化学信息:
化学名 | (2S,3S)-2-[[(2S,3S)-2-[acetyl(methyl)amino]-3-methylpentanoyl]amino]-N-[(2S,3R)-3-hydroxy-1-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxobutan-2-yl]-3-methylpentanamide | |
简称 | Epoxomicin | |
别名 |
BU-4061T, BU 4061T |
|
中文名 | N/A | |
化学式 | C28H50N4O7 | |
分子量 | 554.72 | |
CAS号 | 134381-21-8 | |
纯度 | 98% | |
溶剂/溶解度 |
Water<1mg/ml; DMSO10mg/ml; Ethanol<1mg/ml |
|
溶液配制 | 5mg加入0.9ml DMSO,或者每5.55mg加入1ml DMSO,配制成10mM溶液。SD7198-10mM用DMSO配制。 |
生物信息:
产品描述 | Epoxomicin (BU-4061T) is a potent anti-tumor agent isolated from Actinomycetes that is used as a selective and irreversible inhibitor of the 20S proteasome. | ||||
信号通路 | Metabolism; Proteases | ||||
靶点 | 20S proteasome | - | - | - | - |
IC50 | - | - | - | - | - |
体外研究 | Epoxomicin inhibits proteasome activity in cell growth assays with an IC50 value of 4nM and demonstrates potent cytotoxicity against B16-F10, HCT116, and Moser solid tumor cells, as well as P388 and K562 leukemia cells with IC50 values ranging from 2-44nM. By inhibiting osteoblast proteasome activity, epoxomicin stimulates bone formation at concentrations as low as 10nM. | ||||
体内研究 | Intraperitoneal injection of 1.5mg/kg epoxomicin given daily for two weeks induces Parkinson's-like symptoms in rats and addition of 100nM epoxomicin to rat ventral midbrain cultures results in apoptosis specific to dopaminergic neurons. | ||||
临床实验 | N/A | ||||
特征 | N/A |
相关实验数据(此数据来自于公开文献,碧云天并不保证其有效性):
酶活性检测实验 | |
方法 | N/A |
细胞实验 | |
细胞系 | N/A |
浓度 | N/A |
处理时间 | N/A |
方法 | N/A |
动物实验 | |
动物模型 | N/A |
配制 | N/A |
剂量 | N/A |
给药方式 | N/A |
产品编号 | 产品名称 | 包装 |
SD7198-10mM | Epoxomicin (20S proteasome抑制剂) | 10mM×0.2ml |
SD7198-5mg | Epoxomicin (20S proteasome抑制剂) | 5mg |
SD7198-25mg | Epoxomicin (20S proteasome抑制剂) | 25mg |
— | 说明书 | 1份 |
保存条件:
-20℃保存,至少一年有效。5mg和25mg包装也可室温保存,至少6个月有效。如果溶于非DMSO溶剂,建议分装后-80℃保存,预计6个月内有效。